ES2053196T3 - Metodo para la produccion de un radioinmunoconjugado. - Google Patents

Metodo para la produccion de un radioinmunoconjugado.

Info

Publication number
ES2053196T3
ES2053196T3 ES90909718T ES90909718T ES2053196T3 ES 2053196 T3 ES2053196 T3 ES 2053196T3 ES 90909718 T ES90909718 T ES 90909718T ES 90909718 T ES90909718 T ES 90909718T ES 2053196 T3 ES2053196 T3 ES 2053196T3
Authority
ES
Spain
Prior art keywords
compounds
production
radio
treatment
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90909718T
Other languages
English (en)
Inventor
Maurits Willem Geerlings
Franciscus Michael Kaspersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of ES2053196T3 publication Critical patent/ES2053196T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION ACTUAL SE REFIERE A LA UTILIZACION DEL ACTINIO O DE UNO DE SUS FILIALES EN LA RADIOINMUNOTERAPIA. TAMBIEN SE PROPORCIONAN OTROS INMUNODERIVADOS QUE COMPRENDEN UN ISOTOPO, UN AGENTE SERVIDOR Y UN ANTICUERPO DE CONCENTRACION LENTA. LA INVENCION INCLUYE TAMBIEN, COMPUESTOS FARMACEUTICOS QUE COMPRENDEN DICHOS INMUNODERIVADOS, ASI COMO, OTROS COMPUESTOS QUE COMPRENDEN UNO O MAS AGENTES EXPULSORES. ESTOS COMPUESTOS EN CONSONANCIA CON LA INVENCION SON, PARTICULARMENTE, UTILES PARA EL TRATAMIENTO DE MICROMETASTASIS EN TERAPIAS COADYUVANTES, ASI COMO, PARA EL TRATAMIENTO DE TUMORES LOCALIZADOS.
ES90909718T 1989-06-19 1990-06-19 Metodo para la produccion de un radioinmunoconjugado. Expired - Lifetime ES2053196T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89201591 1989-06-19

Publications (1)

Publication Number Publication Date
ES2053196T3 true ES2053196T3 (es) 1994-07-16

Family

ID=8202415

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90909718T Expired - Lifetime ES2053196T3 (es) 1989-06-19 1990-06-19 Metodo para la produccion de un radioinmunoconjugado.

Country Status (11)

Country Link
US (1) US5246691C1 (es)
EP (1) EP0429624B1 (es)
JP (1) JPH089553B2 (es)
KR (1) KR0179645B1 (es)
AU (1) AU629367B2 (es)
CA (1) CA2034484C (es)
DE (1) DE69007430T2 (es)
DK (1) DK0429624T3 (es)
ES (1) ES2053196T3 (es)
FI (1) FI98707C (es)
WO (1) WO1990015625A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403771B1 (en) * 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
EP0746761A4 (en) * 1993-03-12 1997-02-26 Akzo America Inc PROCESS FOR EXTRACTING RADON 220 FROM A MIXTURE OF RADIOACTIVE ISOTOPES
LU88636A1 (de) * 1995-07-03 1997-01-03 Euratom Verfahren zur Erzeugung von Actinium-225
LU88637A1 (de) * 1995-07-03 1997-01-03 Euratom Verfahren zur Erzeugung von Actinium-225 und Wismut-213 durch Bestrahlung von Radium-226 mit hochenergetischen Gammaquanten
PT842668E (pt) * 1996-11-15 2003-01-31 Euratom Metodo ex-corpore de tratamento de celulas humanas sanguineas
US5809394A (en) * 1996-12-13 1998-09-15 Battelle Memorial Institute Methods of separating short half-life radionuclides from a mixture of radionuclides
US6117413A (en) * 1997-11-12 2000-09-12 Battelle Memorial Institute Radionuclide-binding compound, a radionuclide delivery system, a method of making a radium complexing compound, a method of extracting a radionuclide, and a method of delivering a radionuclide
WO1999036105A2 (en) * 1998-01-16 1999-07-22 Mca Development B.V. USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
US6696551B1 (en) 1999-03-23 2004-02-24 The United States Of America As Represented By The Department Of Health And Human Services 225Ac-HEHA and related compounds, methods of synthesis and methods of use
EP1289570B1 (en) * 2000-06-16 2008-09-10 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of alpha-emitters and uses thereof
US6852296B2 (en) * 2001-06-22 2005-02-08 Pg Research Foundation Production of ultrapure bismuth-213 for use in therapeutic nuclear medicine
US7087206B2 (en) * 2002-04-12 2006-08-08 Pg Research Foundation Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
WO2004062722A2 (en) * 2003-01-08 2004-07-29 Sloan Kettering Institute For Cancer Research Prevention of systemic toxicity during radioimmunotherapy for intravascularly disseminated cancers
NZ595758A (en) * 2003-04-15 2013-02-22 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
DE102004022200B4 (de) * 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
US7618627B2 (en) 2004-06-03 2009-11-17 The Regents Of The University Of California Method of increasing radiation sensitivity by inhibition of beta one integrin
US7157061B2 (en) * 2004-09-24 2007-01-02 Battelle Energy Alliance, Llc Process for radioisotope recovery and system for implementing same
US7736610B2 (en) * 2004-09-24 2010-06-15 Battelle Energy Alliance, Llc Actinium radioisotope products of enhanced purity
DE102006008023B4 (de) * 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
CA2950532C (en) * 2006-09-08 2018-10-23 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
CN104710504B (zh) 2009-07-22 2019-09-13 锕医药股份有限公司 用于制备放射性免疫缀合物的方法
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
US20150157742A1 (en) * 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
EP3409297A1 (en) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
WO2026024644A1 (en) 2024-07-23 2026-01-29 Abdera Therapeutics Inc. 5t4 binding polypeptides and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
EP0282057A3 (en) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates

Also Published As

Publication number Publication date
KR920700690A (ko) 1992-08-10
AU629367B2 (en) 1992-10-01
DE69007430D1 (de) 1994-04-21
JPH04500366A (ja) 1992-01-23
JPH089553B2 (ja) 1996-01-31
DK0429624T3 (da) 1994-05-30
FI98707C (fi) 1997-08-11
AU5857490A (en) 1991-01-08
EP0429624A1 (en) 1991-06-05
KR0179645B1 (en) 1999-03-20
WO1990015625A1 (en) 1990-12-27
CA2034484A1 (en) 1990-12-20
US5246691A (en) 1993-09-21
US5246691C1 (en) 2001-10-09
CA2034484C (en) 2000-08-15
FI98707B (fi) 1997-04-30
DE69007430T2 (de) 1994-07-07
FI910772A0 (fi) 1991-02-18
EP0429624B1 (en) 1994-03-16

Similar Documents

Publication Publication Date Title
ES2053196T3 (es) Metodo para la produccion de un radioinmunoconjugado.
ES2051768T3 (es) Compuestos farmaceuticos mejorados con contenido de metales.
ES2055745T3 (es) Compuestos antigestagenicos y antiestrogenos para el tratamiento de tumores hormono-dependientes.
ES2053763T3 (es) Composiciones estabilizadas de isotiazolonas.
GT199800037A (es) Combinaciones para diabetes de sulfonilurea - glitazona.
ES2137372T3 (es) Solucion antifungica para las uñas.
BR0115087A (pt) Membro radioativo para uso em braquiterapia e métodos de fazer um membro radioativo e de tratar uma condição que responda a terapia por radiação
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
SE8402098D0 (sv) Perfluorkarbonemulsion, framstellning derav samt dess anvendning i terapi
ES469094A1 (es) Metodo para tratamiento de la madera con un agente conserva-dor de la madera,asi como la madera tratada con dicho agenteconservador de la madera
DK0467026T3 (da) Middel til farvning af hår og anvendelse af midlet
ES2042742T3 (es) Procedimiento para preparar furanonas antiinflamatorias.
DE3781182D1 (de) Tamoxifen zur topischen verwendung.
ES527893A0 (es) Procedimiento de obtencion de un agente para el tratamiento de acero fundido
ES2082831T3 (es) Composicion para tratamiento de tejidos con propiedades suavizantes.
FR1315251A (fr) Porte coulissante et basculante, plus particulièrement destinée aux véhicules
ES317850A1 (es) Procedimiento de produccion catalitica de poliuretanos.
DK5384A (da) Cycloaliphatiske farmaceutiske forbindelser
ES2057341T3 (es) Ciclohexenos substituidos como agentes para el sistema nervioso central.
ES2038663T3 (es) Un metodo para preparar una composicion para la aplicacion por via topica, destinada al tratamiento de la enfermedad epitelial hiperproliferativa.
ES2129401T3 (es) Uso de un compuesto terapeutico para el tratamiento de bronquitis.
ES2013687T3 (es) Procedimiento y agente para la conservacion de la piedra.
ES2008097B3 (es) - 2-sustitutivo 4, 4, 7, 7-tetrametil-1,3dioxacicloheptano, su fabricacion y utilizacion como sustancia aromatica
FR1881M (fr) Composition injectable pour réduire le taux de cholestérol sanguin.
ES536439A0 (es) Un procedimiento para producir acero en el que las inclusiones son generalmente de forma esferica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 429624

Country of ref document: ES